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To compare the clinico-pathologic prognostic factors and survival of younger vs older women diagnosed with epithelial ovarian
cancer. Demographic, clinico-pathologic, treatment, and surgery information were obtained from patients with ovarian cancer from
the Surveillance, Epidemiology, and End Results Program from 1988 to 2001 and analysed using Kaplan–Meier estimates. Of 28165
patients, 400 were o30 years (very young), 11601 were 30–60 (young), and 16164 were 460 (older) years of age. Of the very
young, young, and older patients, 261 (65.3%), 4664 (40.2%), and 3643 (22.5%) had stage I–II disease, respectively (Po0.001).
Across all stages, very young women had a significant survival advantage over the young and older groups with 5-year disease-specific
survival estimates at 78.8% vs 58.8 and 35.3%, respectively (Po0.001). This survival difference between the age groups persists even
after adjusting for race, stage, grade, and surgical treatment. Reproductive age (16–40 years) women with stage I–II epithelial ovarian
cancer who received uterine-sparing procedures had similar survivals compared to those who underwent standard surgery (93.3% vs
91.5%, P¼0.26). Younger women with epithelial ovarian cancer have a survival advantage compared to older patients.
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As the most lethal of the gynaecologic malignancies, ovarian
cancer remains the fifth most common cause of cancer-related
death for women in the United States. An estimated 25580 new
cases of ovarian cancer were diagnosed in the United States in the
year 2004, with 16090 deaths associated with this disease (Jemal
et al, 2004). Despite advances in surgical and systemic treatment,
the 5-year survival of advanced stage patients with ovarian cancer
remains below 30% (Nguyen et al, 1993; Parker et al, 1996; Jemal
et al, 2004; Ries et al, 2004). However, invasive epithelial ovarian
cancer is largely a disease of postmenopausal women with
reproductive-age women comprising only 20% of all patients
(Smedley and Sikora, 1985; Swenerton et al, 1985; Plaxe et al, 1993;
Rodriguez et al, 1994). Previous studies on young patients with
ovarian cancer have reported survival rates as high as 75% across
all stages compared to 40% in the overall population.
Some reports have indicated that younger age is not an
independent prognostic factor for improved survival, suggesting
that the survival advantage of the younger patients may be
attributed to the increased frequency of early-stage, lower grade
disease, and tumours of low malignant potential (Massi et al, 1996;
Duska et al, 1999). Nonetheless, several other published studies
have specified age as a significant prognostic factor, with older
patients faring less well than younger women (Smedley and Sikora,
1985; Swenerton et al, 1985; Yancik et al, 1986; Omura et al, 1991;
Gloecker-Ries, 1993; Ries, 1993; Thigpen et al, 1993; Kosary, 1994;
Rodriguez et al, 1994; Lee et al, 1999; Brun et al, 2000; Schildkraut
et al, 2000; Barnholtz-Sloan et al, 2003; Chan et al, 2003; O’Malley
et al, 2003).
Many of these studies are institutional-based analyses compri-
sing a small number of patients. Furthermore, most reports
originated from academic institutions and clinical trials data with
associated biases and outcomes that may not reflect the general
population (Averette et al, 1995; Barnholtz-Sloan et al, 2003; Chan
et al, 2003). Prior studies that have used data from national
registries included information collected from 1973 to 1997
(Yancik et al, 1986; Ries, 1993; Kosary, 1994; Barnholtz-Sloan
et al, 2003). Since that time, there have been important changes
that have affected the care of ovarian cancer patients. In addition,
many studies have not thoroughly evaluated important clinico-
pathologic prognostic factors. Consequently, there are limited
population-based studies with detailed surgical staging and
pathology data that have evaluated the demographics, clinico-
pathologic, and survival outcomes of younger women diagnosed
with epithelial ovarian cancer.
In this study of over 28000 epithelial ovarian cancer patients,
we propose to determine if young age is an independent factor
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sassociated with improved survival and identify the clinico-
pathologic prognostic factors associated with the survival of
younger patients.
MATERIALS AND METHODS
Demographic, clinico-pathological, treatment, and survival infor-
mation on 28165 women diagnosed with primary epithelial
ovarian cancer during the period from 1988 to 2001 were extracted
from the Surveillance, Epidemiology and End Results (SEER)
database of the United States National Cancer Institute. All
patients with low malignant potential tumours of the ovary were
excluded from our analysis. Patients diagnosed with germ cell,
sarcomas, and sex cord stromal histologic cell types were excluded.
Data are reported from 12 population-based registries that
represent approximately 14% of the US population including San
Francisco-Oakland, Connecticut, metropolitan Detroit, Hawaii,
Iowa, New Mexico, Seattle (Puget Sound), Utah, metropolitan
Atlanta, Alaska, San Jose-Monterey, and Los Angeles (Hankey
et al, 1999).
To further define the young patients with epithelial ovarian
cancer, we divided our young patient population into two
subgroups, o30 and 30–60, which we arbitrarily called the very
young and young groups vs the older group 460 years. The race
classifications of the SEER program were categorised into four
groups: White, Black, Asian, and Others. Asians were defined as
Chinese, Japanese, Korean, Vietnamese, and Filipina. All other race
and ethnicity classifications were defined as Others. Surgical
treatment was classified as either absent, uterine-sparing, or
standard. Uterine-sparing surgeries were defined as surgeries that
did not include a hysterectomy whereas standard surgeries
included those reported to have had a hysterectomy and/or radical
debulking.
To analyse distribution patterns in the study cohort and to
determine 5-year disease-specific survival, w
2 tests, and Kaplan–
Meier analysis with log-rank tests were performed for the age
groups defined above. The distributions of demographic, clinical,
histologic, and treatment characteristics were compared using the
w
2 test. Survival analysis was performed using the Kaplan–Meier
estimates of survival probability across all three age groups, and
the Cox-proportional hazards model was used to identify
independent predictors of survival (Figure 1). The outcome of
interest was death from ovarian cancer (disease-specific survival)
and time to death was censored in women who died from causes
other than ovarian cancer. Statistical analysis was performed using
the Intercooled STATA 8.0 program (College Station, TX, USA). A
two-sided P-value o0.05 was considered statistically significant.
RESULTS
28165 patients were diagnosed with primary epithelial ovarian
cancer from 1988 to 2001. We divided our young patient
population into two groups: the very young group (o30 years)
consisting of 400 women and the young group (30–60 years) with
11601 patients. To provide a means for comparison, 16164 older
patients (460 years) were used as controls. The median age of the
young and very young patients was 26 (range: 12–29) and 50 years
(range: 30–60), respectively. In contrast, the median age for the
control group was 72 years (range: 61–101).
Although the majority of patients in the three age groups were
White, they comprised a significantly higher proportion of older
patients as compared to younger patients (78.3% for very young,
83.6% for young, and 89.2% for the older group; Po0.001). In
contrast, Black subjects comprised 7.8% of the very young, 6.1%
young, and only 5.6% of the older age group (Po0.001). Similarly,
other minority groups such as Asians and Hispanics are more
heavily represented in the younger age groups (Table 1).
The very young and young patients were more likely to undergo
a primary surgical procedure at 96.5 and 93.1% compared to 73.0%
in the older age group (Table 2). More specifically, the very young
patients are more likely to receive a uterine-preserving procedure
compared to the older age groups (71.2 vs 14.1 vs 15.6%,
respectively; Po0.001). Of those who underwent standard surgery,
4628 (24.8%), 1715 (9.2%), 7334 (39.2%), and 5018 (26.8%) had
stage I, II, III, and IV disease. Moreover, of the women who had
uterine-sparing procedures, 1393 (32.5%) had stage I disease, 306
(7.1%) stage II, 1343 (31.3%) stage III, and 1243 (29.0%) had stage
IV disease.
In the overall study group, 22.3% had stage I, 8.2% stage II,
35.9% stage III, and 33.7% had stage IV disease. Younger patients
were diagnosed with significantly more early-stage disease than
older patients. In fact, 65.3 and 40.2% of the very young and young
age groups presented with stage I–II disease compared to only
22.5% in the 460 age group (Po0.001). Younger patients were
also more likely to be diagnosed with grade 1 disease with 33.8 and
12.0% of those in the very young and young group having well-
differentiated tumours compared to only 5.4% in the older patients
(Po0.001). In the entire study group, 1411 (4.7%) were clear cell
cancers of the ovary. There were no significant differences in the
various histologic cell types amongst the three age groups.
The overall 5-year disease-specific survivals of women o30, 30–
60, and 460 age groups were 78.8, 58.8, and 35.3%, respectively
(Po0.001; Table 3). Of those with early-stage disease, the very
young and young patients had a significant survival advantage
at 89.7 and 88.8% compared to 74.5% in the older age group
(Po0.001). Similarly, older women with advanced-stage disease
had poorer survival at only 22.1% compared to 55.7 and 36.9%
in the very young and younger women (Po0.001). Younger age
continues to portend for a better prognosis across ethnic,
histologic cell types, and year of diagnosis. Furthermore, younger
age (Po0.001), more recent year of diagnosis (Po0.001), non-
clear cell epithelial histologic cell types (Po0.001), earlier stage of
disease (Stage I vs Stage II vs Stage III vs Stage IV, Po0.001), lower
grade (Po0.001), and surgical treatment (no surgery vs any
surgery, Po0.001) remained as independent prognostic factors
for improved survival (Table 4). When data for patients o30 years,
30–60 and 460 years were analysed, similar results confirming
the importance of age as an independent prognostic factor groups
were found (hazard ratio¼1.20, 95% CI¼1.13–1.28; Po0.001).
Interestingly, reproductive age women, age 16–40, with stage
I–II epithelial ovarian cancer who underwent uterine-sparing
surgical procedures (n¼435) had similar rates of survival
compared to their counterparts (n¼620) who underwent standard
surgery (93.3 vs 91.5%; P¼0.26). Furthermore, there were no
significant survival differences associated with these two surgical
approaches in those with stage I–II non-clear cell epithelial
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Figure 1 Kaplan–Meier disease-specific survival of patients based on age
at diagnosis.
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stumours (94.0% (n¼449) vs 92.4% (n¼719); P¼0.41, Figure 2A)
or stage I–II clear cell cancers (72.9% (n¼20) vs 84.8% (n¼77);
P¼0.73, Figure 2B). Even in patients with stage IIIC disease,
we were unable to demonstrate a statistically significant survival
difference (49.6% (n¼27) vs 68.9% (n¼258), respectively;
P¼0.22).
DISCUSSION
Ovarian cancer is primarily a disease of postmenopausal women.
Previous studies have shown that only 3–17% of patients with
ovarian cancer were age o40 years (Plaxe et al, 1993; Rodriguez
et al, 1994). The reported prognostic significance of age in female
cancers has been inconsistent. Younger age has been shown to be a
poor prognosticator in breast cancer. Recently, Maggard and
others have demonstrated that younger (o35) women with breast
cancer have a poorer prognosis owing to higher stage and grade
of disease at presentation (Yildirim et al, 2000; Biffl et al, 2001;
Xiong et al, 2001; Dubsky et al, 2002; Kothari et al, 2002; Love et al,
2002; Maggard et al, 2003). However, studies on the prognostic
implications of age and ovarian cancer are inconclusive. Although
most reports have shown that younger women with ovarian cancer
have an improved outcome compared to older women and have
lower stage and more well-differentiated tumours (Smedley and
Sikora, 1985; Plaxe et al, 1993; Thigpen et al, 1993; Rodriguez et al,
1994; Chan et al, 2003), others have found that age is not an
independent prognostic factor after adjusting for tumour stage and
grade (Massi et al, 1996; Duska et al, 1999). Moreover, the majority
of these previous studies on ovarian cancer are based on single
Table 1 Demographic data
Total (n¼28165) Age o30 (n¼400) Age 30–60 (n¼11601) Age 460 (n¼16164) v
2
n( % ) n( % ) n( % ) n( % ) P-values
Age at diagnosis
Median (range) 64 (12–101) 26 (12–29) 50 (30–60) 72 (61–101)
Race
White 24424 (86.7%) 313 (78.3%) 9698 (83.6%) 14413 (89.2%) o0.001
a
Non-Hispanic 22487 (92.1%) 258 (82.4%) 8715 (89.9%) 13514 (93.8%)
Hispanic 1937 (7.9%) 55 (17.6%) 983 (10.1%) 899 (6.2%)
Black 1638 (5.8%) 31 (7.8%) 702 (6.1%) 905 (5.6%)
Asian
b 1496 (5.3%) 32 (8.0%) 841 (7.2%) 623 (3.9%)
Other 607 (2.2%) 24 (6.0%) 360 (3.1%) 223 (1.4%)
Year of diagnosis
1988–1992 8277 (29.4%) 157 (39.3%) 3218 (27.7%) 4902 (30.3%) o0.001
1993–1997 10812 (38.4%) 131 (32.8%) 4416 (38.1%) 6265 (38.8%)
1998–2001 9076 (32.2%) 112 (28.0%) 3967 (34.2%) 4997 (30.9%)
aComparing Non-Hispanic, Hispanic, Black, Asian, and Other race; when comparing White, Black, Asian, and other race, Po0.001.
bIncludes Chinese, Japanese, Filipina, Korean,
and Vietnamese.
Table 2 Clinico-pathologic and treatment data
Total (n¼28165) Age o30 (n¼400) Age 30–60 (n¼11601) Age 460 (n¼16164) v
2
n (%) n (%) n (%) n (%) P-values
Surgical treatment
No surgery 5169 (18.4%) 14 (3.5%) 794 (6.8%) 4361 (27.0%) o0.001
Uterus sparing
a 4285 (15.2%) 208 (52.0%) 1559 (13.4%) 2518 (15.6%)
Standard
b 18695 (66.4%) 178 (44.5%) 9242 (79.7%) 9275 (57.4%)
Unknown 16 (0.1%) 0 (0.0%) 6 (0.1%) 10 (0.1%)
Stage at diagnosis
Stage I 6268 (22.3%) 231 (57.8%) 3639 (31.4%) 2398 (14.8%) o0.001
Stage II 2300 (8.2%) 30 (7.5%) 1025 (8.8%) 1245 (7.7%)
Stage III 10113 (35.9%) 75 (18.8%) 3948 (34.0%) 6090 (37.7%)
Stage IV 9484 (33.7%) 64 (16.0%) 2,989 (25.8%) 6431 (39.8%)
Histology
Epithelial 28165 (93.1%) 400 (40.4%) 11601 (94.0%) 16164 (95.6%) o0.001
c
Non-clear cell 26754 (88.5%) 390 (39.4%) 10708 (86.7%) 15656 (92.6%)
Clear cell 1411 (4.7%) 10 (1.0%) 893 (7.2%) 508 (3.0%)
Grade of disease
Grade 1 2398 (8.5%) 135 (33.8%) 1391 (12.0%) 872 (5.4%) o0.001
Grade 2 5119 (18.2%) 97 (24.3%) 2437 (21.0%) 2585 (16.0%)
Grade 3 12374 (43.9%) 54 (13.5%) 5059 (43.6%) 7261 (44.9%)
Unknown grade 8274 (29.4%) 114 (28.5%) 2714 (23.4%) 5446 (33.7%)
aUterus-sparing surgeries, including minimal surgery or surgeries that did not include a hysterectomy.
bStandard surgeries, including surgeries including a hysterectomy and/or
debulking.
cCompares non-clear cell epithelial with clear cell.
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sinstitution experiences, which contain inherent biases such as
patient selection (Plaxe et al, 1993; Duska et al, 1999; Chan et al,
2003). In addition, owing to the low prevalence of young patients
diagnosed with invasive ovarian cancer, these studies have also
been limited by a small number of patients, inclusion of low
malignant potential tumours, germ cell or sex cord stromal
tumours, and unstaged cancers. European analyses on ovarian
cancer incidence rates include studies carried out by Smedley and
Sikora (1985), La Vecchia et al (1992), dos Santos Silva and
Swerdlow (1995), Koper et al (1996), Nelson et al (1999). Given the
limitations from prior reports, we proposed to perform a large
population-based study to evaluate the clinico-pathologic char-
acteristics between younger and older patients with epithelial
ovarian cancer. Furthermore, we sought to determine if younger
age is an independent prognostic factor for improved survival and
analyze the safety of uterine-sparing surgery in reproductive-age
women.
The finding that young women tend to have more indolent grade
1 tumours may contribute to their earlier stage at presentation and
overall good prognosis. Although lower grade and earlier stage
may partially explain the better survival of younger patients with
ovarian cancer, younger age was an independent prognostic factor
for improved survival in our multivariable analysis. Beyond
conventional pathologic prognostic factors, other important
molecular markers include p53 expression, Her2neu, and DNA
ploidy can also help elucidate the survival differences between
younger and older women (Trope et al, 2000; Nagai et al, 2001;
Skirnisdottir et al, 2001; Chan et al, 2004; Nishimura et al, 2005;
Serrano-Olvera et al, 2006). Studies have shown that younger
patients had tumours with higher microvascular density which
may be associated with an improved response to paclitaxel/
platinum-based chemotherapy (Hartmann et al, 1994; Kosary,
1994; Chan et al, 2004). Our results reflect that of other studies
showing that younger age is an independent prognosticator for
improved survival (Yancik et al, 1986; Ries, 1993; Kosary, 1994;
Rodriguez et al, 1994; Barnholtz-Sloan et al, 2003; O’Malley et al,
2003). Nevertheless, this current reports is one of the largest
population-based studies that has evaluated the demographic and
clinico-pathologic prognostic factors associated with the survival
of younger women with ovarian cancer using detailed surgical
staging and pathologic information.
Some studies have reported that younger women are able to
tolerate more intensive chemotherapeutic regimens which may
explain the better outcome in these patients (Thigpen et al, 1993;
Kosary, 1994). On the other hand, case-controlled studies from
single academic institutions adjusting for the experience of
surgeon, extent of surgery, and adjuvant chemotherapy, younger
age remained a significant independent factor for improved
survival (Duska et al, 1999; Chan et al, 2003). In addition, Chan
et al (2003) showed that younger age was an important prognostic
factor for improved survival independent of age-associated
determinants such as performance status. Similar findings were
also reported by Thigpen et al (1993) who analysed a large series of
patients with stage III and IV invasive epithelial ovarian cancer
from six Gynecologic Oncology Group trials where strict guidelines
were maintained to ensure that all patients underwent similar
surgical procedures and standard adjuvant chemotherapy.
Given the large number of patients in this current study, we were
able to divide our patient population into three subsets; those
o30, 30–60, and 460 years. It was not surprising to find that the
women o30 were more likely to have grade 1 and early-stage
Table 3 Disease-specific 5-year survival by demography and clinico-pathology
Total (n¼28,165) Age o30 Age 30–60 (n¼11601) Age 460 (n¼16164) Log-rank
%7s.e. (n¼400) n (%) n (%) P-values
Ovarian cancer 46.170.4 78.872.4 58.870.6 35.370.5 o0.001
Stage I–II 82.970.5 89.772.1 88.870.5 74.570.8 o0.001
Stage III–IV 27.970.4 55.775.2 36.970.7 22.170.5 o0.001
Race
White 45.770.4 78.672.6 59.270.6 34.970.5 o0.001
Non-Hispanic 45.270.4 79.372.8 59.270.6 34.570.5 o0.001
Hispanic 52.171.4 74.077.2 59.372.0 42.372.1 o0.001
Black 41.771.6 83.777.6 52.172.3 30.272.1 o0.001
Asians
a 55.371.6 88.276.5 58.672.1 49.572.5 o0.001
Year of diagnosis
b
1988–1992 43.570.6 81.773.2 57.370.9 32.070.7 o0.001
1993–1997 46.870.5 74.674.1 58.570.8 37.070.7 o0.001
Histology
Epithelial 46.170.4 78.872.4 58.870.6 35.370.5 o0.001
Non-clear cell 45.170.4 78.372.4 58.170.6 34.470.5 o0.001
Clear cell 65.071.5 100.070.0 67.371.8 60.272.5 ¼0.004
Grade of disease
Grade 1 83.870.9 90.772.8 89.071.0 74.371.7 o0.001
Grade 2 57.170.8 78.574.7 67.271.1 46.271.2 o0.001
Grade 3 37.170.6 25.879.2 44.870.9 31.670.7 o0.001
aIncludes Chinese, Japanese, Filipina, Korean, and Vietnamese.
b1998–2001 time period not included as follow-up is not mature enough to yield 5-year survivals.
Table 4 Multivariate analysis
Hazard ratio Confidence interval P-value
Stage of disease
a 1.93 (1.89–1.97) Po0.001
Histologic cell type
b 1.27 (1.15–1.40) Po0.001
Age at diagnosis
c 1.02 (1.02–1.02) Po0.001
Grade of disease
d 1.02 (1.01–1.03) Po0.001
Year of diagnosis
c 0.99 (0.98–0.99) Po0.001
Surgical treatment
e 0.69 (0.68–0.71) Po0.001
Race/Ethnicity
f 0.99 (0.96–1.02) P¼0.71
aStage I vs Stage II vs Stage III vs Stage IV.
bNon-clear cell epithelial cancer vs clear cell
cancer.
cAs a continuous variable.
dGrade 1 vs Grade 2 vs Grade 3 vs unknown
Grade.
eNo surgery vs any surgery.
fWhite vs Black vs Asians vs Others.
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scancers. In fact, over 40% of ovarian cancers in the age 30–60
cohort had early-stage disease compared to less than 25% in the
older cohort.
The potential role of fertility-sparing surgery in reproductive age
women diagnosed with ovarian cancer has received considerable
attention. In a national survey of ovarian cancer evaluating women
age o25 years with ovarian malignancies, Rodriguez et al (1994)
demonstrated that the rate of fertility-sparing surgery has
increased from 46 to 70% over the 5-year study period. In this
current report, we showed that uterine-sparing surgery was
performed on 38.1% of reproductive age women with early-stage
epithelial ovarian cancer. However, because the SEER database
does not provide information regarding the extent of surgical
debulking and desire to retain fertility, it is difficult to definitively
validate or refute the possibilities that uterine-sparing surgery may
represent suboptimally debulked patients in older women or be
indicative of a desire to retain fertility in younger patients with
advanced-stage disease. Nonetheless, our analyses did not find
any survival difference between these women who underwent a
uterine-sparing procedure compared to those that had standard
surgeries in early-stage cancers (P¼0.26). In a sub-analysis
comparing women with stage I–II non-clear cell vs clear cell
cancers, we found that there was still no survival difference based
on the type of surgical procedure performed (non-clear cell
epithelial cancer, P¼0.41; clear cell, P¼0.73). We recognise that
the survival of young patients appears to have decreased over the
two time periods (1988–1992; 1993–1997); however, the difference
was not statistically significant (P¼0.47) and is likely owing to
the small number of patients within each group (o200). We also
performed an additional analysis on the use of uterine-sparing
surgeries between these two groups and identified a trend towards
an increase in the use of conservative surgery over time, though,
again, statistically insignificant (49.7–55.0%; P¼0.66). Thus, it is
unlikely that uterine-sparing surgeries could have contributed to
the suggested findings. Although this retrospective data suggests
that uterine-sparing surgeries may be considered in reproductive-
age women, patients should be counselled appropriately with an
understanding of the risks.
Our study was limited by the lack of information on surgeon
specialty, extent of residual disease, adjuvant chemotherapy, and
subsequent cytoreductive surgeries. Given that our data was
derived from a nationwide cancer registry, it has shortcomings
with respect to detailed clinical information such as family history,
presenting symptoms, performance status, and time from symp-
tom to presentation which may help to enhance our understanding
of the underlying causes for the survival differences between the
age groups. As with other large population-based series, our report
was also limited by a lack of central pathology review. To
determine if there are significant discrepancies between registry
and referral pathologists, Piver et al (2000) reviewed slides from
a large cancer registry and found a 95.3% complete agreement
between pathologists on the disease site of origin. Moreover,
there was a 61.7% complete histopathologic agreement with only
1% of cases that were considered as having major differences.
Similarly, Tyler et al (1991) performed slide reviews on 477
women diagnosed with ovarian, breast, or endometrial cancer and
compared the diagnoses of pathologists contributing to tumour
registries affiliated with the SEER program to an expert panel of
three gynaecologic pathologists. They found an overall agreement
of 97% for overall cancers, and the agreement for major cellular
subtypes of ovarian cancer was 73% for endometrioid and 100%
for clear cell cancers.
The strength of this study lies in the large number of young
patients with surgically staged invasive ovarian cancer, offering the
ability to perform detailed, stratified analyses without sacrificing
statistical strength. Furthermore, we excluded all women diag-
nosed with low malignant potential tumours, sarcomas, germ cell,
and sex cord stromal tumours. Given that younger women are
more likely to be diagnosed with borderline tumours, the inclusion
of these patients may partially explain the better survival of
younger women in prior studies. Additionally, this current study is
one of the largest series to date of unselected patients spanning
across 12 US regions, allowing for the attenuation of selection and
surveillance biases often associated with clinical trials and studies
from single academic institutions. Because SEER cancer registries
are consistent with those for the entire country, the results from
this population-based study can be generalised to the national
population (Hankey et al, 1999). Most importantly, SEER uses
several quality control measures to ensure accuracy; thus, they are
able to maintain the highest level of certification of data quality
and completeness as reported by the Northern American Associa-
tion of Central Cancer Registries. SEER adheres to strict quality
assessment measures by ensuring the accuracy of sample cases by
reabstracting data from the medical records annually. Based on
a recent studies by Virnig et al (2002), these authors found a
98% completeness in each sample case with a 490% rate in the
accuracy of reporting adjuvant therapy (Virnig et al, 2002;
Maggard et al, 2003). In addition, the database also appears to
be accurate for major surgical procedures (Cooper et al, 2002).
In summary, this is one of the largest studies to date defining the
status of young patients diagnosed with epithelial ovarian cancer.
We found that younger patients have a better survival compared to
their older cohort. Clearly, early stage and lower grade are in part
responsible for the improved survival of these young women.
However, after controlling for these clinico-pathologic prognostic
factors, the younger group still had a better prognosis, suggests
that there maybe other underlying factors such as tumour biology
that can explain these findings. This analysis also suggests that
reproductive-age women who undergo surgical staging should be
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Figure 2 Kaplan–Meier disease-specific survival of reproductive age
patients (age 16–40 years) with stage I–II (A) epithelial and (B) clear cell
ovarian cancer.
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soffered conservative treatment with uterine-sparing surgeries.
Moreover, given the overall encouraging outcome of younger
women diagnosed with ovarian cancer, these patients need to be
treated aggressively. Further research to investigate the potential
biologic and molecular difference between epithelial ovarian
tumours in various age groups is warranted.
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